Withanage T, Alcalay R, Krichevsky O, Wachtel E, Mazor O, Patchornik G
Antibodies (Basel). 2025; 14(1).
PMID: 39982226
PMC: 11843901.
DOI: 10.3390/antib14010011.
Wen X, Liu A, Song J, Leng C, Wang J, Russo B
ACS Pharmacol Transl Sci. 2025; 8(2):394-408.
PMID: 39974635
PMC: 11833721.
DOI: 10.1021/acsptsci.4c00460.
Fadaie M, Shahmoradi Z, Khanahmad H
Res Pharm Sci. 2025; 19(6):729-745.
PMID: 39911897
PMC: 11792711.
DOI: 10.4103/RPS.RPS_145_24.
Bai S, Cui Y, Liao Q, Yi H, Liao Z, Zhang G
Viruses. 2025; 17(1).
PMID: 39861905
PMC: 11768982.
DOI: 10.3390/v17010116.
Guo Y, Sun T, Li M, Chen Z, Liu Y, Luo X
Pharm Res. 2025; 42(1):137-149.
PMID: 39806211
PMC: 11785693.
DOI: 10.1007/s11095-024-03807-x.
Single chain fragment variable, a new theranostic approach for cardiovascular diseases.
Zahid R, Wang J, Cai Z, Ishtiaq A, Liu M, Ma D
Front Immunol. 2024; 15:1443290.
PMID: 39735545
PMC: 11671482.
DOI: 10.3389/fimmu.2024.1443290.
Effect of Oral Administration of Collagen Peptide OG-5 on Advanced Atherosclerosis Development in ApoE Mice.
Yang Y, Li B
Nutrients. 2024; 16(21).
PMID: 39519585
PMC: 11547735.
DOI: 10.3390/nu16213752.
Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma.
Morabito F, Martino E, Nizzoli M, Talami A, Pozzi S, Martino M
Eur J Haematol. 2024; 114(1):4-16.
PMID: 39462177
PMC: 11613673.
DOI: 10.1111/ejh.14335.
Biomedical Application of Enzymatically Crosslinked Injectable Hydrogels.
Nam M, Lee J, Cha G
Gels. 2024; 10(10).
PMID: 39451293
PMC: 11507637.
DOI: 10.3390/gels10100640.
A novel anti-CTLA-4 nanobody-IL12 fusion protein in combination with a dendritic cell/tumour fusion cell vaccine enhances the antitumour activity of CD8 T cells in solid tumours.
Jiang M, Cui H, Li T, Yang X, Lu X, Liu A
J Nanobiotechnology. 2024; 22(1):645.
PMID: 39427185
PMC: 11490160.
DOI: 10.1186/s12951-024-02914-6.
Breaking Boundaries: Immunotherapy for Myeloid Malignancies.
Gavrilova T, Schulz E, Mina A
Cancers (Basel). 2024; 16(16).
PMID: 39199554
PMC: 11352449.
DOI: 10.3390/cancers16162780.
Preparation and Application of Alpha Toxin Nanobodies.
Jia Q, Ren H, Zhang S, Yang H, Gao S, Fan R
Vet Sci. 2024; 11(8).
PMID: 39195835
PMC: 11360521.
DOI: 10.3390/vetsci11080381.
Developability considerations for bispecific and multispecific antibodies.
Amash A, Volkers G, Farber P, Griffin D, Davison K, Goodman A
MAbs. 2024; 16(1):2394229.
PMID: 39189686
PMC: 11352713.
DOI: 10.1080/19420862.2024.2394229.
Single-Domain Antibodies as Antibody-Drug Conjugates: From Promise to Practice-A Systematic Review.
Medina Perez V, Baselga M, Schuhmacher A
Cancers (Basel). 2024; 16(15).
PMID: 39123409
PMC: 11311928.
DOI: 10.3390/cancers16152681.
An Immunoreceptor-Targeting Strategy with Minimalistic C3b Peptide Fusion Enhances SARS-CoV-2 RBD mRNA Vaccine Immunogenicity.
Chiu C, Tsai H, Chen J, Hu C, Chen H
Int J Nanomedicine. 2024; 19:7201-7214.
PMID: 39050877
PMC: 11268571.
DOI: 10.2147/IJN.S463546.
Single domain antibodies from camelids in the treatment of microbial infections.
De Greve H, Fioravanti A
Front Immunol. 2024; 15:1334829.
PMID: 38827746
PMC: 11140111.
DOI: 10.3389/fimmu.2024.1334829.
AlbuCatcher for Long-Acting Therapeutics.
Rho J, Lee J, Kwon I
ACS Omega. 2024; 9(21):22990-23000.
PMID: 38826564
PMC: 11137731.
DOI: 10.1021/acsomega.4c02303.
Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity.
Tschongov T, Konwar S, Busch A, Sievert C, Hartmann A, Noris M
Front Immunol. 2024; 15:1383123.
PMID: 38799460
PMC: 11117068.
DOI: 10.3389/fimmu.2024.1383123.
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
Wu Y, Zhu M, Sun B, Chen Y, Huang Y, Gai J
J Nanobiotechnology. 2024; 22(1):256.
PMID: 38755613
PMC: 11097425.
DOI: 10.1186/s12951-024-02521-5.
A broadly applicable protein-polymer adjuvant system for antiviral vaccines.
Wang C, Geng Y, Wang H, Ren Z, Hou Q, Fang A
EMBO Mol Med. 2024; 16(6):1451-1483.
PMID: 38750307
PMC: 11178928.
DOI: 10.1038/s44321-024-00076-4.